On March 10, 2026, the innovative B7-H3-targeting antibody-drug conjugate (ADC) YL201 for injection, developed by MediLink Therapeutics, was granted Breakthrough Therapy Designation by the Center for Drug Evaluation of China’s National Medical Products Administration. The designated indication is in combination with Serplulimab for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
YL201 is an innovative ADC specifically targeting B7H3. The B7H3 protein is overexpressed on malignant cells and cancer-initiating cells of various tumor types but has restricted expression in normal tissue, highlighting its potential as an ADC drug target. YL201 was developed utilizing MediLink’s Tumor Microenvironment Activable LINker-payload (TMALIN®) technology conjugated with a highly specific B7H3 antibody. Currently, YL201 is being investigated in a variety of solid tumors and has entered pivotal-stage trials in Small Cell Lung Cancer and Nasopharyngeal Carcinoma in China.
### Authoritative Clinical Data: Significant Efficacy and Favorable Safety
In March 2025, the international top-tier journal *Nature Medicine* published data from the Phase 1/1b clinical trial of YL201 in patients with advanced solid tumors. This study, encompassing 312 patients, demonstrated:
- **Overall Efficacy:** Among 287 evaluable patients, the objective response rate (ORR) was an impressive 40.8%, including 2 patients achieving complete response (CR) and 115 achieving partial response (PR). The disease control rate (DCR) reached 83.6%.
- **Extensive-Stage Small Cell Lung Cancer (ES-SCLC):** In patients previously treated with platinum-based chemotherapy, the ORR was 63.9%, the DCR was 91.7%, and the median progression-free survival (mPFS) was 6.3 months.
- **Nasopharyngeal Carcinoma (NPC):** Among 70 patients, the ORR was 48.6%, the DCR was 92.9%, with 2 patients achieving complete response. The median duration of response (mDOR) was as long as 8.4 months.
These data fully confirm the potent anti-tumor activity and manageable safety profile of YL201 across multiple types of advanced solid tumors, laying a solid foundation for subsequent clinical research and broader application.
### Beijing South Region Oncology Hospital International Department: Your Bridge to International Medicine
Beijing South Region Oncology Hospital International Department is consistently dedicated to introducing globally leading cancer diagnosis and treatment technologies and medications. We closely follow cutting-edge research progress and maintain strong collaborations with top-tier scientific institutions both domestically and internationally, striving to provide international patients with timely access to breakthrough treatment options including YL201.
Our International Patient Services team can provide you with:
- **Personalized Medical Assessment:** A multidisciplinary team (MDT) will comprehensively evaluate your medical records to determine if ADC therapy is suitable for your condition.
- **Streamlined Access to Care:** Assistance with obtaining visas for China, scheduling specialist consultations, arranging interpretation services, and coordinating hospital admission for a worry-free experience.
### Contact Us Now for More Information
If you or a loved one is facing challenges related to extensive-stage small cell lung cancer, nasopharyngeal carcinoma, or other advanced solid tumors, and wish to learn more details about the cutting-edge ADC therapy or assess treatment opportunities, please contact the Beijing South Region Oncology Hospital International Department immediately. Our International Patient Services specialists will respond to your inquiry within 24 hours.
**Contact Information:**
- **Tel:** 400-880-3716���
- **WeChat:** 17801183037
- **Email:**
100085_010@163.com
myimmnet@163.com
We understand that the path of cancer treatment is arduous, but every breakthrough signifies new hope. Beijing South Region Oncology Hospital International Department wishes to stand with you, leveraging expert medical technology and warm, compassionate care, to jointly overcome cancer and embrace the dawn of life.
Post time: Mar-24-2026